Telix Pharmaceuticals Financials

TLX Stock   25.74  0.80  3.21%   
Financial data analysis helps to confirm if markets are presently mispricing Telix Pharmaceuticals. We have analyzed and interpolated twenty-six available drivers for Telix Pharmaceuticals, which can be compared to its competition. The stock experiences an unexpected upward trend. Watch out for market signals. Check odds of Telix Pharmaceuticals to be traded at 30.89 in 90 days. Key indicators impacting Telix Pharmaceuticals' financial strength include:
Operating Margin
0.0949
PE Ratio
170.2
Profit Margin
0.0762
EPS Estimate Current Year
0.1983
Return On Equity
0.2049
  
Please note, the imprecision that can be found in Telix Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Telix Pharmaceuticals. Check Telix Pharmaceuticals' Beneish M Score to see the likelihood of Telix Pharmaceuticals' management manipulating its earnings.

Telix Pharmaceuticals Stock Summary

Telix Pharmaceuticals competes with Aneka Tambang, Commonwealth Bank, Commonwealth Bank, Australia, and ANZ Group. Telix Pharmaceuticals is entity of Australia. It is traded as Stock on AU exchange.
Foreign Associate
  USA
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentAustralia Stock View All
ExchangeAustralian Securities Exchange
ISINAU000000TLX2
Business Address55 Flemington Road,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitetelixpharma.com
Phone61 3 9093 3855
You should never invest in Telix Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Telix Stock, because this is throwing your money away. Analyzing the key information contained in Telix Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Telix Pharmaceuticals Key Financial Ratios

Telix Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Telix Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Telix Pharmaceuticals over time and compare it to other companies across industries.

Telix Pharmaceuticals Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets102.6M164.4M109.8M260.6M398.3M418.2M
Net Debt(42.5M)(75.7M)(19.5M)(105.9M)(105.8M)(100.5M)
Retained Earnings(48.1M)(93.0M)(173.5M)(272.8M)(263.7M)(250.5M)
Accounts Payable7.0M5.8M11.9M16.8M32.8M34.5M
Cash44.6M77.9M22.0M116.3M123.2M63.5M
Net Receivables13.0M14.2M20.8M39.4M64.8M68.0M
Total Liab31.9M84.4M106.2M178.4M249.4M261.9M
Total Current Assets58.7M93.6M47.5M173.2M224.8M236.1M
Common Stock115.9M167.1M170.8M371.0M446.3M468.6M
Other Current Liab3.2M10.1M19.3M55.8M100.5M105.5M
Other Liab20.3M57.4M67.8M80.0M92.0M96.6M
Net Tangible Assets28.1M19.8M(53.6M)21.0M18.9M10.2M
Other Assets82K183K212K4.0M4.6M4.8M
Long Term Debt Total1.6M1.4M1.9M9.8M11.3M11.8M
Inventory542K633K3.5M8.5M17.3M18.2M
Other Current Assets530K859K1.2M9.1M19.5M20.5M
Net Invested Capital70.8M79.4M2.2M83.3M158.1M166.0M
Short Long Term Debt469K264K19K964K867.6K911.0K
Net Working Capital48.1M73.7M9.6M87.7M67.4M56.9M
Short Term Debt490K767K632K641K1.6M874.9K
Intangible Assets41.9M59.2M55.7M59.0M104.8M56.3M
Long Term Debt292K95K0.03.3M8.2M8.6M
Capital Stock115.9M167.1M170.8M371.0M446.3M246.2M

Telix Pharmaceuticals Key Income Statement Accounts

201920202021202220232024 (projected)
Interest Expense2.4M1.2M189K406K13.1M13.8M
Operating Income(40.3M)(49.3M)(81.2M)(73.2M)51.9M54.5M
Ebitda(36.2M)(44.9M)(70.1M)(92.8M)23.0M24.1M
Income Before Tax(42.8M)(60.3M)(99.0M)(98.6M)3.1M3.2M
Net Income(27.9M)(44.9M)(80.5M)(104.1M)5.2M5.5M
Income Tax Expense(14.9M)(15.4M)(18.5M)5.5M(2.1M)(2.2M)
Total Revenue3.5M5.2M7.6M160.1M496.7M521.5M
Gross Profit(11.9M)(16.9M)(29.8M)29.3M308.5M323.9M
Ebit(40.4M)(49.8M)(75.2M)(98.2M)16.2M17.0M
Research Development21.2M23.1M34.1M57.9M128.8M135.3M
Cost Of Revenue15.4M22.1M37.4M130.8M188.2M197.6M
Tax Provision(3.3M)(3.0M)45K5.5M(2.1M)(2.0M)
Net Interest Income(2.3M)(1.1M)(5.2M)(6.7M)(12.8M)(12.1M)
Interest Income2.4M67K163K1K1.0M626.2K

Telix Pharmaceuticals Key Cash Accounts

201920202021202220232024 (projected)
Change In Cash18.8M33.3M(55.9M)94.3M6.9M6.6M
Net Borrowings(1.2M)(904K)(936K)1.7M2.0M2.1M
Depreciation4.2M4.9M5.2M5.4M6.9M7.3M
Other Non Cash Items9.7M18.7M31.5M41.0M60.5M63.5M
Capital Expenditures468K322K1.3M13.9M10.8M11.3M
Net Income(27.9M)(44.9M)(80.5M)(104.1M)5.2M5.5M
Change To Netincome659K10.2M18.6M35.7M41.1M43.2M
Investments(468K)(1.1M)(2.7M)(17.0M)(25.5M)(24.2M)
Free Cash Flow(23.8M)1.6M(60.7M)(77.8M)13.1M13.7M
End Period Cash Flow44.6M77.9M22.0M116.3M123.2M72.1M

Telix Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Telix Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Telix Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Telix Pharmaceuticals competition to find correlations between indicators driving Telix Pharmaceuticals's intrinsic value. More Info.
Telix Pharmaceuticals is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about  0.39  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Telix Pharmaceuticals is roughly  2.57 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telix Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Telix Pharmaceuticals Systematic Risk

Telix Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Telix Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Telix Pharmaceuticals correlated with the market. If Beta is less than 0 Telix Pharmaceuticals generally moves in the opposite direction as compared to the market. If Telix Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Telix Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Telix Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Telix Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.

Telix Pharmaceuticals Common Stock Shares Outstanding Over Time

Telix Pharmaceuticals December 18, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Telix Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Telix Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Telix Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Telix Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Telix Pharmaceuticals's daily price indicators and compare them against related drivers.

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.